secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001493152-24-042277
Event type: leadership
Sentiment:  negative
Materiality: 0.50
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma CDO resigns; CMO and VP Clinical Dev to assume duties
-----------------------------------------------------------------------

- Chief Development Officer Theresa Matkovits resigned effective October 23, 2024, to pursue another opportunity.
- Resignation not due to material disagreement or change in company direction.
- James J. Ferguson (CMO) and Susan Johansson (VP Clinical Dev) will fill her responsibilities.
- Company continues to work toward partnership on MAT2203, its oral amphotericin B formulation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/0001493152-24-042277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224042277/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-042277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer